1 Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012;10:712–21.
2 Oka P, Parr H, Barberio B, et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020;5:908–17.
3 Gralnek IM, Hays RD, Kilbourne A, et al. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology 2000;119:654–60.
4 Frändemark Å, Törnblom H, Jakobsson S, et al. Work Productivity and Activity Impairment in Irritable Bowel Syndrome (IBS): A Multifaceted Problem. Am J Gastroenterol 2018;113:1540–1549.
5 Spiegel B, Harris L, Lucak S, et al. Developing valid and reliable health utilities in irritable bowel syndrome: results from the IBS PROOF Cohort. Am J Gastroenterol 2009;104:1984–91.
6 Lacy BE, Pimentel M, Brenner DM, et al. ACG Clinical Guideline: Management of Irritable Bowel Syndrome. Am J Gastroenterol 2021;116:17–44.
7 National Institute for Health and Care Excellence. Irritable bowel syndrome in adults: diagnosis and management. Clinical guideline 61. [https://www.nice.org.uk/guidance/cg61]. Update 2017. Accessed June 6, 2021.
8 Ford AC, Lacy BE, Harris LA, et al. Effect of Antidepressants and Psychological Therapies in Irritable Bowel Syndrome: An Updated Systematic Review and Meta-Analysis. Am J Gastroenterol 2019;114:21–39.
9 Laird KT, Tanner-Smith EE, Russell AC, et al. Comparative efficacy of psychological therapies for improving mental health and daily functioning in irritable bowel syndrome: A systematic review and meta-analysis. Clin Psychol Rev 2017;51:142–152.
10 Taft TH. Improving access to gut-brain therapies for IBS. Lancet Gastroenterol Hepatol 2019;4:816–818.
11 Whitfield, G. Group cognitive–behavioural therapy for anxiety and depression. Advances in Psychiatric Treatment 2010;16:219–27.
12 Black CJ, Thakur ER, Houghton LA, et al. Efficacy of psychological therapies for irritable bowel syndrome: systematic review and network meta-analysis. Gut 2020;69:1441–51.
13 Vollmer A, Blanchard EB. Controlled comparison of individual versus group cognitive therapy for irritable bowel syndrome. Behavior Therapy 1998;29:19–33.
14 Tkachuk GA, Graff LA, Martin GL,et al. Randomized Controlled Trial of Cognitive– Behavioral Group Therapy for Irritable Bowel Syndrome in a Medical Setting. J Clin Psychol Med Setting 2003;10:57–69.
15 Craske MG, Wolitzky-Taylor KB, Labus J, et al. A cognitive-behavioral treatment for irritable bowel syndrome using interoceptive exposure to visceral sensations. Behav Res Ther 2011;49:413–21.
16 Longstreth GF, Thompson WG, Chey WD, et al.Functional bowel disorders. Gastroenterology 2006;130:1480–91.
17 Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology 2016;150:1393– 1407.
18 Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395–402.
19 Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001;16:606–613.
20 Kikuchi S, Oe Y, Sasaki Y, et al. Group cognitive behavioural therapy (GCBT) versus treatment as usual (TAU) in the treatment of irritable bowel syndrome (IBS): a study protocol for a randomized controlled trial. BMC Gastroenterol 2020;20:29.
21 Patrick DL, Drossman DA, Frederick IO, et al.Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci 1998;43:400–11.
22 U.S. Department of Health and Human Services Food and Drug Administration. Multiple endpoints in clinical trials: guidance for industry. [https://www.fda.gov/media/102657/download]. Published 2017. Accessed August 13, 2021.
23 Drossman D, Morris CB, Hu Y, et al. Characterization of health related quality of life (HRQOL) for patients with functional bowel disorder (FBD) and its response to treatment. Am J Gastroenterol 2007;102:1442–53.
24 Svedlund J, Sjödin I, Dotevall G. GSRS--a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci1988;33:129–134.
25 Spitzer RL, Kroenke K, Williams JB, et al. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006;166:1092–97.
26 Brooks R. EuroQol: the current state of play. Health Policy 1996;37:53–72.
27 Gordon S, Ameen V, Bagby B, et al.Validation of irritable bowel syndrome Global Improvement Scale: an integrated symptom end point for assessing treatment efficacy. Dig Dis Sci 2003;48:1317–1323.
28 Blanchard EB, Schwarz SP. Clinically significant changes in behavioral medicine. Behav Assess 1988;10:171–88.
29 Sozu T, Sugimoto T, Hamasaki T, et al. Sample Size Determination in Clinical Trials with Multiple Endpoints. Springer Heidelberg 2015. https://doi.org/10.1007/978-3-319-22005-5 (e-book)
30 Kanazawa M, Drossman DA, Shinozaki M, et al. Translation and validation of a Japanese version of the irritable bowel syndrome-quality of life measure (IBS-QOL-J). Biopsychosoc Med 2007;1:6.
31 Koloski NA, Jones M, Kalantar J, et al.The brain--gut pathway in functional gastrointestinal disorders is bidirectional: a 12-year prospective population-based study. Gut 2012;61:1284–90.
32 Kennedy T, Jones R, Darnley S, et al. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomized controlled trial. BMJ 2005;331:435.
33 van Dulmen AM, Fennis JF, Bleijenberg G. Cognitive-behavioral group therapy for irritable bowel syndrome: effects and long-term follow-up. Psychosom Med 1996;58:508–514.
34 Furukawa TA, Noma H, Caldwell DM, et al. Waiting list may be a nocebo condition in psychotherapy trials: a contribution from network meta-analysis. Acta Psychiatr Scand 2014; 130:181–92.
35 Gold SM, Enck P, Hasselmann H, et al. Control conditions for randomised trials of behavioural interventions in psychiatry: a decision framework. Lancet Psychiatry 2017;4:725– 732.
36 Patterson B, Boyle MH, Kivlenieks M, et al. The use of waitlists as control conditions in anxiety disorders research. J Psychiatr Res 2016;83:112–20.
37 U.S. Department of Health and Human Services Food and Drug Administration. Guidance for Industry Irritable Bowel Syndrome—Clinical Evaluation of Drugs for Treatment. FDA: Silver Spring, MD, 2012 [https://www.fda.gov/media/78622/download]. Published 2012. Accessed August 9, 2021.